Another buying opp? Lol.
Even after results, co. Might get a small pop and then results will be scrutinized based upon small N. End result is right back where you started.

waiting years for next trial.

New year same stuff. Too many other companies making real progress to bet the farm on this ish.

Even BP are conducting ph3 Rett trial with more participants and for a longer duration to verify efficacy. Here’s one below with 184 participants again ph 3.

https://clinicaltrials.gov/ct2/show/NCT04181723?recrs=ad&cond=Rett+Syndrome&draw=2&rank=2

One or two primary outcomes have a level of subjectivity to them due to caretakers note taking. In addition the duration of trial is short compared to other trials. IMO after looking at current and previous trials for rett, we will have a ph3 trial for Rett.

Maybe missling will buy 375 shares. Lol.

There’s no way in hell Missling will miss PDD full enrollment by year end. Heck I don’t like the guy but I do have confidence he’ll make this enrollment since he just stated it should be complete by YE.

Trials are going to fail. Anavex will never have a drug make it to the market.

Anavex is a threat to itself. Declining market cap and scooping poop does not equate to confidence.

Anavex is a sad company. Very sad. With sad CEO.

Hard time completing enrollment for even small trial. I thought good news travels fast and tight group of rett families would run to join the trial. Families talk. Oh, not for this poopy scoopy company and not this rubbish.

Immaterial. Misleading can’t even properly complete a 10k, 10Q, and posters missing N’s. When company stated in last 10 that millions missed in prior quarter was Immaterial..

That’s means the company does not dot i’s and cross t’s. Company has a history mistakes.

Immaterial=== money given by others was immaterial. Company words not mine.

Misleading can’t even get theses primary trialscomplete before the one person goes to the extension trial. OJT rookie ceo is over his head now.

That better ran company went up more than $25 bucks during the day today.


The better ran company is opening 90 sites. Sp was $17 this spring and now $ 70 plus. Market Cap exploded today and made us a lot of $$$$$$$$$$$$$$$$$


????????????????????
Spurred by the totality of data from Phase 1a/b testing, investigators are now enrolling subjects in the GAIN trial, which is targeting an enrollment of up to 570 patients with mild to moderate AD at ~90 sites in the United States and Europe.

Like scooping poop is confirmation of 2 73 MOA and that was not 5 years ago.

CEO has prior experience as a CEO and has prior experience in AD unlike Misleading. 90 sites and 4 or 5 countries in Europe.


From PR.
Spurred by the totality of data from Phase 1a/b testing, investigators are now enrolling subjects in the GAIN trial, which is targeting an enrollment of up to 570 patients with mild to moderate AD at ~90 sites in the United States and Europe.

https://gaintrial.com/en/study-sites

How a better company has AD trial running in several countries

Here are the US sites. Started recruiting 9/19 and will conclude first quarter 2021.

A better ran company is opening 90 sites. Sp was $17 this spring and now $50 plus. Market Cap is exploding.

From PR.
Spurred by the totality of data from Phase 1a/b testing, investigators are now enrolling subjects in the GAIN trial, which is targeting an enrollment of up to 570 patients with mild to moderate AD at ~90 sites in the United States and Europe.

Precision medicine is the shiny new buzzword over the last few years. It’s just another word for we can’t fix everyone so let’s try to fix a few. Key word TRY. It failed once in general population so now it’s precision.

Anavex equals bad leadership and wishful science.

Immaterial is what Anavex referred to a millions plus dollar mistake in the last 10k. Immaterial. Not the words I would use but I guess they were down playing there monetary incentives.
Immaterial.

Reply to

You're kidding, right?

How can it not be "extremely bullish to run a trial there" when Australia is helping to pay for the AD study?!!!

Have you seen the videos of the Australian AD participants that have been interviewed on TV from 4 - 5 years ago?

Note, I stated it is a negative sentiment.

Buying puts to protect an investment is perceived as negative and it is factored into ownership.

I don’t perceive that’s as being overly bullish to run a trial there. Diminishing returns for sites especially if goal is 450.
Bad math.

Reply to


Or.... It may be that there have never been 224 patients enrolled in a single AD trial in Australia before. That seems more likely

Tutes ownerships is not always on the side of buying or positive. The last time I checked, Tutes had put options in AVXL and normally a negative sentiment. These options are factored in ownership.

This AD trial will fail just like Neurotrope and it is appropriate to compare the two.

There is a major difference. It is much easier to fill enrollment for mild trials than severe. Just saying.

But again appropriate comparison for trial failure.

Wow. Sounds like inside information but it’s not true.


Something is wrong with AD
We know AD enrollment is 450 patients and we are NOT even half way enrolled but let’s give them 224 patients. AD trial started 16 months ago. So 224 patients divided by16 months is 14 patients a month at best. Just 14 patients a month and Missling is bragging about historical enrollment.

A CEO bragging about this enrollment should be fired.
He knew he could not complete enrollment with the sites available THIS Delay is on purpose.

Something is wrong with AD efficacy.

Add in conducting AD in location know for Slow trials for AD.
Then factor a trial that is twice as long as it needs to be.
SOC got approved with a trial half as long by the FDA.
This trial is being purposefully delayed or Missling is horrible at math.

Something is wrong with AD
We know AD enrollment is 450 patients and we are NOT even half way enrolled but let’s give them 224 patients. AD trial started 16 months ago. So 224 patients divided by16 months is 14 patients a month at best. Just 14 patients a month and Missling is bragging about historical enrollment.

A CEO bragging about this enrollment should be fired.
He knew he could not complete enrollment with the sites available THIS Delay is on purpose.

Something is wrong with AD efficacy.

Add in conducting AD in location know for Slow trials for AD.
Then factor a trial that is twice as long as it needs to be.
SOC got approved with a trial half as long by the FDA.
This trial is being purposefully delayed or Missling is horrible at math.

We know AD enrollment is 450 patients and we are NOT even half way enrolled but let’s give them 224 patients. AD trial started 16 months ago. So 224 patients divided by16 months is 14 patients a month at best. Just 14 patients a month and Missling is bragging about historical enrollment.

A CEO bragging about this enrollment should be fired.
He knew he could not complete enrollment with the sites available THIS Delay is on purpose.

Something is wrong with AD efficacy.

Page 38 is the quote stating 2021 from McFarlane.

https://www.hammond.com.au/documents/research-reports/404-2018-hammondcare-researchreport/file

Diminishing returns for AD enrollment in Australia.
I was here for AD now the wait is realistically 2022 at the earliest. It takes time to set up sites.

First time CEO does not specialize in project management.

Fails PM and fails in other areas



Fire Misleading

International enrollment was stated last year in original PR for AD. As I stated several times, Australia enrollment was falling short for full enrollment.
Now he stated NO set target for AD enrollment.
Didn’t even commit to 2020.

Like I said many times, he is pushing back AD,,,

Something is wrong in AD.

How many lies are we about to here from Misleading?
This first time CEO needs to be replaced.
I’ve continued to reduce my position over the years.
Opportunity costs to hold was just to significant and I put that cash to work.

It’s one thing for one to think you are not sharp. Then you open your mouth and prove you are not sharp.

Conversation is enrollment. Placebo and drug both enrolled 100%.

I see why people view co as scamavex.

Welcome to the placebo effect. It’s real.

Reply to


We still have not had an explanation for the outliers that achieved strong response with near no A2-73 concentration and those who had low response despite high concentration..


It’s been 2 or 3 years no explanation. How about patients did not have Alzheimer’s. It’s as good as an explanation as the one that has been offered.

Placebo is performing as well as drug. That’s the early read since placebo patients are enrolling in extension trial at same pace.

Slow enrollment and placebo performing just as well.

Patients taking placebo are enrolling in the extension study.
I don’t view that as a sign of efficacy for the drug. I view that as placebo effect and people want hope.

SOC got approved after 6 month trial. Anavex did not even try to move forward until 2018 with AD.

Anavex could have moved forward after the first read out. But instead waited years. Had cash in hand but waited for years.

SOC got approved after 6 month trial. If goal is get drug approved Anavex has wasted years. The standard of care to get new treatment to market is even lower now than it was years ago.

Clay is here. LOL. Guess what direction Anavex is going soon?.

Wait for it. Wait for it.

I know another buying opportunity. LOL.

Low standards. Mcfugal is an associate professor.

Price drops after missling opens his mouth. Run up will be short. Shorts.